Global Gastroesophageal Reflux Disease Therapeutics Market Size study & Forecast, by Drug Type (Antacids, H2 Receptor Blockers, Proton Pump Inhibitors (PPIs), Pro-kinetic agents), and Regional Analysis, 2022-2029

Description

List of Tables

Global Gastroesophageal Reflux Disease Therapeutics Market is valued at approximately USD 5.18 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 1.76% over the forecast period 2022-2029. Gastroesophageal reflux disease (GERD) is a chronic condition in which stomach acid and other contents flow back up into the esophagus, causing symptoms such as heartburn, regurgitation, and difficulty swallowing. Normally, a muscular ring called the lower esophageal sphincter (LES) prevents stomach contents from flowing back into the esophagus, but in GERD, this ring is weakened or relaxed, allowing stomach acid and other contents to escape into the esophagus. GERD can be caused by a variety of factors, including obesity, pregnancy, certain medications, and a hiatal hernia (a condition in which part of the stomach pushes up into the chest through the diaphragm). Treatment for GERD typically involves lifestyle modifications (such as avoiding trigger foods, losing weight, and quitting smoking) and medications to reduce the amount of acid in the stomach. In severe cases, surgery may be necessary to strengthen the LES or repair a hiatal hernia. The goal of GERD therapeutics is to reduce the amount of acid in the stomach and decrease the severity of symptoms. The market demand is primarily driven by the factors such as the increasing geriatric population, coupled with increasing awareness of GERD and its associated symptoms among patients and healthcare providers, which is leading to earlier diagnosis and treatment which in turn is driving the demand for GERD therapeutics.

In addition, the increasing prevalence of GERD is increasing worldwide, primarily due to changing dietary habits, increasing obesity rates, and an aging population. This has resulted in a growing patient population seeking treatment, which is driving the demand for GERD therapeutics. The National Library of Medicine reported that globally, there were 783.95 million GERD cases in 2019, thus, in turn, these factors are expected to escalate the demand for GERD Therapeutics in the global market. Furthermore, there have been significant technological advancements in GERD treatment options, such as minimally invasive surgery and endoscopic treatments, which are driving the demand for these treatments, as well as there is increasing demand for OTC GERD medications due to their easy availability and affordability. This presents an opportunity for companies to expand their OTC offerings in the GERD therapeutics market presenting lucrative opportunities for market growth over the forthcoming years. However, poor medication pipeline and patient mortality are restricting the market growth over the forecast period of 2022-2029.

The key regions considered for the Global Gastroesophageal Reflux Disease Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the growing use of GERD therapeutics as a result of the disease's rising incidence in the local population. Whereas, Asia Pacific is also expected to grow at the highest growth rate over the forecasting period. Factors such as rising incidences of the ailment, rising knowledge of its treatment among the target market, and rising emphasis on the part of major market participants to diversify their product lines are burgeoning the market growth in the forecasting years.

Major market players included in this report are:

GlaxoSmithKline plc
Pfizer, Inc.
Sanofi S.A.
Johnson & Johnson Pvt. Ltd.
Glenmark Pharmaceuticals Ltd
Camber Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited.
Ironwood Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc.
Adcock Ingram

Recent Developments in the Market:

In July 2022, Adcock Ingram introduced dexlansoprazole modified release, a novel proton pump inhibitor. Professor Ronnie Fass of Ohio's Case Western Reserve University delivered the event's keynote address (United States). Prof. Fass is a recognised authority in gastroesophageal reflux disease and its diagnosis and treatment (GERD).
In June 2022, Glenmark Pharmaceuticals Ltd acquired the authorized generic versions of some over-the-counter medications from Wockhardt Ltd in the United States. The company's wholly-owned subsidiary Glenmark Pharmaceuticals Inc. in the USA has acquired the approved abbreviated new drug applications (ANDAs) for famotidine tablets (10 mg and 20 mg) used to treat and prevent ulcers in the stomach and intestine, as well as Lansoprazole delayed-release capsules USP, 15 mg, a medication used to treat indigestion, heartburn, and acid reflux.
In March 2022, Phantom Pharmaceuticals' FDA-approved medication Vonoprazan, which was created for the treatment of GERD, is now offered over the counter in Japan and other Asian nations. Also, due to the rising demand for GERD therapies in the region, a number of firms have increased their presence in Asia.

Global Gastroesophageal Reflux Disease Therapeutics Market Report Scope:

Historical Data: 2019-2020-2021

Base Year for Estimation: 2021

Forecast period: 2022-2029

Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered: Drug Type, Region

Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World

Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Drug Type:

Antacids
H2 Receptor Blockers
Proton Pump Inhibitors (PPIs)
Pro-kinetic agents

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
ROLA
Rest of the World

Chapter 1. Executive Summary

1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
- 1.2.1. Gastroesophageal Reflux Disease Therapeutics Market, by Region, 2019-2029 (USD Billion)
- 1.2.2. Gastroesophageal Reflux Disease Therapeutics Market, by Drug Type, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption

Chapter 2. Global Gastroesophageal Reflux Disease Therapeutics Market Definition and Scope

2.1. Objective of the Study
2.2. Market Definition & Scope
- 2.2.1. Scope of the Study
- 2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates

Chapter 3. Global Gastroesophageal Reflux Disease Therapeutics Market Dynamics

3.1. Gastroesophageal Reflux Disease Therapeutics Market Impact Analysis (2019-2029)
- 3.1.1. Market Drivers
  - 3.1.1.1. Increasing geriatric population.
  - 3.1.1.2. Rising awareness towards GERD Therapeutics.
  - 3.1.1.3. Increasing prevalence of GERD.
- 3.1.2. Market Challenges
  - 3.1.2.1. Poor medication pipeline and patient mortality.
- 3.1.3. Market Opportunities
  - 3.1.3.1. Technological advancements in GERD treatment options.
  - 3.1.3.2. Increasing demand for over-the-counter (OTC) GERD medications

Chapter 4. Global Gastroesophageal Reflux Disease Therapeutics Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
4.3. PEST Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Gastroesophageal Reflux Disease Therapeutics Market, by Drug Type

6.1. Market Snapshot
6.2. Global Gastroesophageal Reflux Disease Therapeutics Market by Drug Type, Performance - Potential Analysis
6.3. Global Gastroesophageal Reflux Disease Therapeutics Market Estimates & Forecasts by Drug Type 2019-2029 (USD Billion)
6.4. Gastroesophageal Reflux Disease Therapeutics Market, Sub Segment Analysis
- 6.4.1. Antacids
- 6.4.2. H2 Receptor Blockers
- 6.4.3. Proton Pump Inhibitors (PPIs)
- 6.4.4. Pro-kinetic agents

Chapter 7. Global Gastroesophageal Reflux Disease Therapeutics Market, Regional Analysis

7.1. Gastroesophageal Reflux Disease Therapeutics Market, Regional Market Snapshot
7.2. North America Gastroesophageal Reflux Disease Therapeutics Market
- 7.2.1. U.S. Gastroesophageal Reflux Disease Therapeutics Market
  - 7.2.1.1. Drug Type breakdown estimates & forecasts, 2019-2029
- 7.2.2. Canada Gastroesophageal Reflux Disease Therapeutics Market
7.3. Europe Gastroesophageal Reflux Disease Therapeutics Market Snapshot
- 7.3.1. U.K. Gastroesophageal Reflux Disease Therapeutics Market
- 7.3.2. Germany Gastroesophageal Reflux Disease Therapeutics Market
- 7.3.3. France Gastroesophageal Reflux Disease Therapeutics Market
- 7.3.4. Spain Gastroesophageal Reflux Disease Therapeutics Market
- 7.3.5. Italy Gastroesophageal Reflux Disease Therapeutics Market
- 7.3.6. Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market
7.4. Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market Snapshot
- 7.4.1. China Gastroesophageal Reflux Disease Therapeutics Market
- 7.4.2. India Gastroesophageal Reflux Disease Therapeutics Market
- 7.4.3. Japan Gastroesophageal Reflux Disease Therapeutics Market
- 7.4.4. Australia Gastroesophageal Reflux Disease Therapeutics Market
- 7.4.5. South Korea Gastroesophageal Reflux Disease Therapeutics Market
- 7.4.6. Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market
7.5. Latin America Gastroesophageal Reflux Disease Therapeutics Market Snapshot
- 7.5.1. Brazil Gastroesophageal Reflux Disease Therapeutics Market
- 7.5.2. Mexico Gastroesophageal Reflux Disease Therapeutics Market
- 7.5.3. Rest of Latin America Gastroesophageal Reflux Disease Therapeutics Market
7.6. Rest of The World Gastroesophageal Reflux Disease Therapeutics Market

Chapter 8. Competitive Intelligence

8.1. Top Market Strategies
8.2. Company Profiles
- 8.2.1. GlaxoSmithKline plc
  - 8.2.1.1. Key Information
  - 8.2.1.2. Overview
  - 8.2.1.3. Financial (Subject to Data Availability)
  - 8.2.1.4. Product Summary
  - 8.2.1.5. Recent Developments
- 8.2.2. Pfizer, Inc.
- 8.2.3. Sanofi S.A.
- 8.2.4. Johnson & Johnson Pvt. Ltd.
- 8.2.5. Glenmark Pharmaceuticals Ltd
- 8.2.6. Camber Pharmaceuticals, Inc.
- 8.2.7. Takeda Pharmaceutical Company Limited.
- 8.2.8. Ironwood Pharmaceuticals, Inc.
- 8.2.9. Phathom Pharmaceuticals, Inc.
- 8.2.10. Adcock Ingram

Chapter 9. Research Process

9.1. Research Process
- 9.1.1. Data Mining
- 9.1.2. Analysis
- 9.1.3. Market Estimation
- 9.1.4. Validation
- 9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption

LIST OF TABLES

TABLE 1. Global Gastroesophageal Reflux Disease Therapeutics Market, report scope
TABLE 2. Global Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by Region 2019-2029 (USD Billion)
TABLE 3. Global Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by Drug Type 2019-2029 (USD Billion)
TABLE 4. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 5. Global Gastroesophageal Reflux Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 6. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 7. Global Gastroesophageal Reflux Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 8. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 9. Global Gastroesophageal Reflux Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 10. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 11. Global Gastroesophageal Reflux Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 12. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 13. Global Gastroesophageal Reflux Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 14. U.S. Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 15. U.S. Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 16. U.S. Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 17. Canada Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 18. Canada Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 19. Canada Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 20. UK Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 21. UK Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 22. UK Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 23. Germany Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 24. Germany Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 25. Germany Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 26. France Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 27. France Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 28. France Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 29. Italy Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 30. Italy Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 31. Italy Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 32. Spain Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 33. Spain Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 34. Spain Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 35. RoE Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 36. RoE Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 37. RoE Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 38. China Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 39. China Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 40. China Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 41. India Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 42. India Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 43. India Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 44. Japan Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 45. Japan Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 46. Japan Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 47. South Korea Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 48. South Korea Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 49. South Korea Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 50. Australia Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 51. Australia Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 52. Australia Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 53. RoAPAC Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 54. RoAPAC Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 55. RoAPAC Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 56. Brazil Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 57. Brazil Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 58. Brazil Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 59. Mexico Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 60. Mexico Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 61. Mexico Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 62. RoLA Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 63. RoLA Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 64. RoLA Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 65. Row Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 66. Row Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 67. Row Gastroesophageal Reflux Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 68. List of secondary sources, used in the study of global Gastroesophageal Reflux Disease Therapeutics Market
TABLE 69. List of primary sources, used in the study of global Gastroesophageal Reflux Disease Therapeutics Market
TABLE 70. Years considered for the study
TABLE 71. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

FIG 1. Global Gastroesophageal Reflux Disease Therapeutics Market, research methodology
FIG 2. Global Gastroesophageal Reflux Disease Therapeutics Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Gastroesophageal Reflux Disease Therapeutics Market, key trends 2021
FIG 5. Global Gastroesophageal Reflux Disease Therapeutics Market, growth prospects 2022-2029
FIG 6. Global Gastroesophageal Reflux Disease Therapeutics Market, porters 5 force model
FIG 7. Global Gastroesophageal Reflux Disease Therapeutics Market, pest analysis
FIG 8. Global Gastroesophageal Reflux Disease Therapeutics Market, value chain analysis
FIG 9. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
FIG 10. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
FIG 11. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
FIG 12. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
FIG 13. Global Gastroesophageal Reflux Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
FIG 14. Global Gastroesophageal Reflux Disease Therapeutics Market, regional snapshot 2019 & 2029
FIG 15. North America Gastroesophageal Reflux Disease Therapeutics Market 2019 & 2029 (USD Billion)
FIG 16. Europe Gastroesophageal Reflux Disease Therapeutics Market 2019 & 2029 (USD Billion)
FIG 17. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market 2019 & 2029 (USD Billion)
FIG 18. Latin America Gastroesophageal Reflux Disease Therapeutics Market 2019 & 2029 (USD Billion)
FIG 19. Global Gastroesophageal Reflux Disease Therapeutics Market, company Market share analysis (2021)